Literature DB >> 6669942

Serum antibodies to Bacteroides species in chronic inflammatory bowel disease.

M Tvede, S Bondesen, O H Nielsen, S N Rasmussen.   

Abstract

It has been proposed that the presence of elevated serum titres against various Bacteroides species among patients with chronic inflammatory bowel disease (CIBD) may yield aetiological, pathogenic, or prognostic information. Using a crossed immunoelectrophoretic method, we investigated circulating antibodies against four Bacteroides species in 122 patients with CIBD (80 with ulcerative colitis (UC) and 42 with Crohn's disease (CD)) and in 32 patients with the irritable colon syndrome. In this cross-sectional study we found raised titre scores (greater than 0) among 26% of the patients with CD, among 46% of the patients with UC, and among 34% of the patients with the irritable colon syndrome. These differences are not significant. There were no correlations between the antibody titres and the duration of the disease, the clinical disease activity, or the site of the disease. Furthermore, the antibody titres yielded no prognostic information as to the necessity of surgery--that is, colectomy and/or small-bowel resection.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6669942     DOI: 10.3109/00365528309182095

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  15 in total

1.  Autoantibodies to molecular targets in neutrophils in patients with ulcerative colitis.

Authors:  J Brimnes; O H Nielsen; A Wiik; N H Heegaard
Journal:  Dig Dis Sci       Date:  1999-02       Impact factor: 3.199

2.  Comparative studies of superoxide production by microbial wall product-primed neutrophils in ulcerative colitis.

Authors:  Sara Elsøe Nielsen; Ben Vainer; Ole Haagen Nielsen
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

3.  Diallyl trisulfide inhibits tumor necrosis factor-alpha expression in inflammed mucosa of ulcerative colitis.

Authors:  Ai-Ping Bai; Qin Ouyang; Ren-Wei Hu
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

4.  Abnormal metabolism of arachidonic acid in chronic inflammatory bowel disease: enhanced release of leucotriene B4 from activated neutrophils.

Authors:  O H Nielsen; I Ahnfelt-Rønne; J Elmgreen
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

5.  Release of leukotriene B4 and 5-hydroxyeicosatetraenoic acid during phagocytosis of artificial immune complexes by peripheral neutrophils in chronic inflammatory bowel disease.

Authors:  O H Nielsen; J Elmgreen; B S Thomsen; I Ahnfelt-Rønne; A Wiik
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

6.  Insulin-like growth factor binding protein 3 in inflammatory bowel disease.

Authors:  Irena Kirman; Richard Larry Whelan; Suvinit Jain; Sara Elsøe Nielsen; Jakob Benedict Seidelin; Ole Haagen Nielsen
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

7.  Specificity of antibodies secreted by hybridomas generated from activated B cells in the mesenteric lymph nodes of patients with inflammatory bowel disease.

Authors:  L P Chao; J Steele; C Rodrigues; J Lennard-Jones; J L Stanford; C Spiliadis; G A Rook
Journal:  Gut       Date:  1988-01       Impact factor: 23.059

8.  Longitudinal analyses of gut mucosal microbiotas in ulcerative colitis in relation to patient age and disease severity and duration.

Authors:  Alemu Fite; Sandra Macfarlane; Elizabeth Furrie; Bahram Bahrami; John H Cummings; Douglas T Steinke; George T Macfarlane
Journal:  J Clin Microbiol       Date:  2012-12-26       Impact factor: 5.948

9.  Serum interferon activity in inflammatory bowel disease. Arachidonic acid release and lipoxygenation activated by alpha-class interferon in human neutrophils.

Authors:  O H Nielsen; J Elmgreen; I Ahnfelt-Rønne
Journal:  Inflammation       Date:  1988-04       Impact factor: 4.092

10.  Involvement of interleukin-4 and -10 in inflammatory bowel disease.

Authors:  O H Nielsen; T Køppen; N Rüdiger; T Horn; J Eriksen; I Kirman
Journal:  Dig Dis Sci       Date:  1996-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.